# Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer

> **NCT00243854** · PHASE1 · COMPLETED · sponsor: **Indiana University** · enrollment: 8 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Tarceva

## Key facts

- **NCT ID:** NCT00243854
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2010-08
- **Final completion:** 2011-10
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2014-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00243854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00243854, "Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00243854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*